We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Factor Xa-Based Antithrombin Assay Evaluated

By LabMedica International staff writers
Posted on 15 Nov 2011
A recently introduced antithrombin assay based on Factor Xa (FXa) has been evaluated on four different analyzers. More...


The INNOVANCE Antithrombin test is a new FXa-based chromogenic assay for automated quantification of functionally active anti-thrombin (AT) on coagulation analyzers.

Scientists working at Siemens Healthcare Diagnostic Products GmbH (Marburg, Germany) collaborated with investigators from the UK, Italy and another institution in Germany. They used clinical surplus plasma samples from 225 patients and 151 apparently healthy individuals from four different study sites to assay antithrombin.

The Siemens' INNOVANCE Antithrombin assay demonstrated on all analyzers repeatability coefficients of variation (CVs) ≤ 3.2% and within-device and between-run CVs ≤ 6.9%. The reference intervals of all analyzers are comparable with 2.5th percentiles between 80% and 85% of normal. The Siemens' INNOVANCE Antithrombin and the Factor IIa-based BerichromAT III (A) methods demonstrated good concordance with very high correlation coefficients.

The INNOVANCE Antithrombin method exhibited an excellent comparability with the STA Antithrombin III assay (Diagnostica Stago; Asnières sur Seine, France) and an acceptable comparability with the Coamatic LR Antithrombin assay (Instrumentation Laboratory, Bedford, MA, USA). The 31 patients with congenital deficiency were identified with all assays except for the patients carrying the P41L heparin-binding site mutation, which was only identified with the INNOVANCE Antithrombin and the STA Antithrombin III methods.

The authors concluded that this multicenter study demonstrates that the INNOVANCE antithrombin assay is precise and reliable to aid in the diagnosis of antithrombin deficiency. The advantages of this assay compared to the other methods were the higher sensitivity for heparin-binding site mutations, the liquid ready-to-use reagents, and the absence of interference by direct thrombin inhibitors. The study was published in October 2011, in the journal International Journal of Laboratory Hematology.

Related Links:
Siemens Healthcare Diagnostic Products
Diagnostica Stago
Instrumentation Laboratory


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
New
Automatic Hematology Analyzer
LABAS F9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Immunology

view channel
Image: How the predictive test works (Photo courtesy of QMUL)

World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment

Rheumatoid arthritis (RA) is a chronic condition affecting 1 in 100 people in the UK today, causing the immune system to attack its joints. Unlike osteoarthritis, which is caused by wear and tear, RA can... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.